Description
Single-chamber ventricular leadless pacemakers do not support atrial pacing or consistent atrioventricular synchrony. A dual-chamber leadless pacemaker system consisting of two devices implanted percutaneously, one in the right atrium and one in the right ventricle, would make leadless pacemaker therapy a treatment option for a wider range of indications.
Learning Objectives
- Assess the safety and feasibility of dual chamber leadless pacing.
- Discuss acute and medium-term complications of dual chamber leadless pacing.
- Communicate the benefits and limitations of dual chamber AV synchronous leadless pacing.
Article Authors and Podcast Contributors
Article Authors
Reinoud E. Knops, MD, PhD, Vivek Y. Reddy, MD, James E. Ip, MD, Rahul Doshi, MD, Derek V. Exner, MD, MPH, Pascal Defaye, MD, Robert Canby, MD, Maria Grazia Bongiorni, MD, Morio Shoda, MD, Gerhard Hindricks, MD, Petr Neuzil, MD, Mayer Rashtian, MD, Karel T.N. Breeman, MD, Jordan R. Nevo, MS, Leonard Ganz, MD, Chris Hubbard, MBA, and Daniel J. Cantillon, MD
Podcast Contributors
Prashanthan Sanders, MBBS, PhD, FHRS, of University of Adelaide
Suneet Mittal, MD, FHRS, of The Valley Hospital
Roopinder K. Sandhu, MD, MPH, FHRS, of Cedars-Sinai Medical Center
Disclosures
All relevant financial relationships have been mitigated.Host Disclosure(s):
P. Sanders: Research (Contracted Grants for PIs Named Investigators Only): Boston Scientific, Abbott, Medtronic, PaceMate, Becton Dickinson, CathRx; Advisory Committee Membership: Medtronic, Boston Scientific, PaceMate, CathRx
Contributor Disclosure(s):
S. Mittal: Honoraria/Speaking/Consulting Fee: Biosense Webster, Medtronic, Haemonetics, AltaThera Pharmaceuticals, AtriCure, Inc., Boston Scientific, CVRx Inc., Implicity, Impulse Dynamics USA, Philips, Abbott, ARCA Biopharma Inc., Baylis Medical, BMS/Pfizer Alliance, Catawba, CathVision, Octagos
R. Sandhu: Research (Contracted Grants for PIs Named Investigators Only): NIH, Bayer Healthcare Pharmaceuticals
Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.